GT Biopharma Analyst Ratings
GT Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/05/2023 | 96.08% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 09/13/2022 | 390.2% | HC Wainwright & Co. | $25 → $5 | Maintains | Buy |
| 05/24/2021 | 2350.98% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/13/2021 | 1958.82% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 03/17/2021 | 2350.98% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 01/05/2023 | 96.08% | EF 赫頓 | → 2 美元 | 啟動覆蓋範圍 | → 保持 |
| 2022 年 9 月 13 日 | 390.2% | HC 溫賴特 & 有限公司. | 25 美元 → 5 美元 | 維護 | 購買 |
| 2021 年 5 月 24 日 | 2350.98% | HC 溫賴特 & 有限公司. | → 25 美元 | 啟動覆蓋範圍 | → 購買 |
| 2021 年 4 月 13 日 | 1958.82% | B. 萊利證券 | → 21 美元 | 啟動覆蓋範圍 | → 購買 |
| 03/17/2021 | 2350.98% | 羅斯資本 | → 25 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for GT Biopharma (GTBP)?
GT 生物製藥（GTBP）的目標價格是多少？
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by EF Hutton on January 5, 2023. The analyst firm set a price target for $2.00 expecting GTBP to rise to within 12 months (a possible 96.08% upside). 2 analyst firms have reported ratings in the last year.
EF 赫頓於 2023 年 1 月 5 日報導了 GT 生物製藥（納斯達克股票代碼：GTBP）的最新價格目標。該分析師公司設定了 2.00 美元的價格目標，預計 GTBP 將在 12 個月內上升（可能是 96.08% 的上行情況）。2 家分析師公司在去年報告了評級。
What is the most recent analyst rating for GT Biopharma (GTBP)?
GT 生物製藥（GTBP）的最新分析師評級為何？
The latest analyst rating for GT Biopharma (NASDAQ: GTBP) was provided by EF Hutton, and GT Biopharma initiated their hold rating.
GT 生物製藥（納斯達克股票代碼：GTBP）的最新分析師評級由 EF 赫頓提供，GT 生物製藥發起了其持有評級。
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
GT 生物製藥（GTBP）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on January 5, 2023 so you should expect the next rating to be made available sometime around January 5, 2024.
分析師在進行了廣泛的研究後到達股票評級，其中包括通過公共財務報表，與 GT Bioharma 的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。GT 生物製藥的最後評級於 2023 年 1 月 5 日提交，因此您應該期望下一個評級將在 2024 年 1 月 5 日左右的某個時候提供。
Is the Analyst Rating GT Biopharma (GTBP) correct?
分析師評級 GT 生物製藥（GTBP）是否正確？
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a initiated with a price target of $0.00 to $2.00. The current price GT Biopharma (GTBP) is trading at is $1.02, which is within the analyst's predicted range.
雖然評級是主觀的，並且會改變，但最新的 GT 生物製藥（GTBP）評級啟動，目標價格為 0.00 美元至 2.00 美元。目前的價格 GT 生物製藥（GTBP）的交易價格為 1.02 美元，這是分析師的預測範圍內。
譯文內容由第三人軟體翻譯。